Dr. Scarpato highlights case-based discussion on intermediate-risk NMIBC

The phase 2a open-label dose ascending study to assess the safety, tolerability, and efficacy of VMB-100 in female patients with moderate SUI is expected to begin in the first half of 2024.

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

Although low, men experienced a higher risk for erectile dysfunction and hypogonadism after being prescribed semaglutide for weight loss; however, further questions remain.

Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.

At 5 years from CCH injection, curvature and plaque volume were associated with patient satisfaction in the treatment of their Peyronie’s disease.

Severe SUI was defined as 3 or more pads daily and severe erectile dysfunction was defined as an International Index of Erectile Function score of 10 or lower.